CANBRIDGE-B News

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

CANbridge Pharmaceuticals' Auditor Steps Down; Successor Named

MT NewswiresDec 6 04:51 ET

CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies

Moomoo NewsNov 15 02:37 ET

CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A

MT NewswiresOct 25 07:07 ET

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Simply Wall StOct 2 19:40 ET

BeiHai Kangcheng-B (01228): CAN103 for the treatment of Gaucher's Disease (GD) qualifies for priority review.

Beihai Kangcheng-B (01228) announced CAN103 (Vilapine β) for the treatment of Gaucher's disease (GD)...

Zhitong FinanceSep 30 08:15 ET

Express News | CANbridge Pharmaceuticals Inc - Grant of Priority Review Status of Can103 for Treatment of Gaucher Disease

ReutersSep 30 08:14 ET

Beihai Kangcheng-B (01228.HK) appoints Fangxin Li as a non-executive director.

Grondragon September 30th |Beihai Kangcheng-B(01228.HK) announced that Fangxin Li has been appointed as a non-executive director and a member of the board of directors' remuneration committee, effective from September 30, 2024. The board of directors has also received the resignation letter of Hu Zhengguo as a non-executive director and a member of the board of directors' remuneration committee, effective from the date of effectiveness.

Gelonghui FinanceSep 30 05:41 ET

Express News | CANbridge Pharmaceuticals Inc - James Qun Xue Will Assume Interim Duties and Responsibilities of CFO

ReutersSep 30 05:37 ET

Express News | CANbridge Pharmaceuticals Inc - Glenn Hassan Has Tendered His Resignation as Chief Financial Officer

ReutersSep 30 05:36 ET

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease has been granted Priority Review Status by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

CANbridgeSep 30 00:49 ET

Canbridge Pharmaceuticals Books Wider Attributable Loss in H1

MT NewswiresSep 27 05:39 ET

CANBRIDGE-B: INTERIM REPORT 2024

HKEXSep 26 18:29 ET · Announcements

Beijing Kanglecheng-B (01228.HK): Richard James Gregory appointed as a member of the audit committee.

On September 2, Geelong announced that due to Chen Kan's plan to spend more time on personal affairs, he has resigned as a non-executive director and a member of the audit committee, effective from September 2, 2024. After Chen Kan's resignation, independent non-executive director Richard James Gregory has been appointed as a member of the audit committee, effective from the effective date.

Gelonghui FinanceSep 2 04:40 ET

Beihai Kangcheng-B (01228.HK) has achieved significant growth in its mid-term performance, with a significant increase in research and development investment.

On August 30th, Gelonghui announced its interim performance. For the six months ended June 30, 2024, the group's revenue increased by CNY 1.7 million to CNY 44.8 million from CNY 43.1 million for the six months ended June 30, 2023. This is mainly due to the company's original plan to strategically focus on rare diseases in 2021, and the transition arrangement of Heidi An's distribution in Hong Kong will end in the second half of 2023. In addition to the sales in Hong Kong by Heidi An, the group's revenue increased by CNY 8.8 million or 24.4% compared to the same period in 2023, mainly due to Maier.

Gelonghui FinanceAug 29 19:42 ET

Express News | CANbridge Pharmaceuticals H1 Gross Profit RMB 29.4 Million

ReutersAug 29 19:33 ET

Express News | CANbridge Pharmaceuticals H1 Revenue RMB 44.8 Million

ReutersAug 29 19:33 ET

Express News | CANbridge Pharmaceuticals H1 Gross Margin 65.7%

ReutersAug 29 19:33 ET

Express News | CANbridge Pharmaceuticals H1 Adjusted Net Income RMB -242.5 Million

ReutersAug 29 19:33 ET